Familial Amyloid Neuropathies - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Familial Amyloid Neuropathies - Pipeline Review, H1 2016

Familial Amyloid Neuropathies - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Familial Amyloid Neuropathies - Pipeline Review, H1 2016
Published May 31, 2016
76 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Familial Amyloid Neuropathies - Pipeline Review, H1 2016, provides an overview of the Familial Amyloid Neuropathies pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies
- The report reviews pipeline therapeutics for Familial Amyloid Neuropathies by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Familial Amyloid Neuropathies therapeutics and enlists all their major and minor projects
- The report assesses Familial Amyloid Neuropathies therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Familial Amyloid Neuropathies

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Familial Amyloid Neuropathies
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devis

  
Source:
Document ID
GMDHC8205IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Familial Amyloid Neuropathies Overview71
Therapeutics Development82
  Pipeline Products for Familial Amyloid Neuropathies Overview81
  Pipeline Products for Familial Amyloid Neuropathies Comparative Analysis91
Familial Amyloid Neuropathies Therapeutics under Development by Companies101
Familial Amyloid Neuropathies Therapeutics under Investigation by Universities/Institutes111
Familial Amyloid Neuropathies Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Familial Amyloid Neuropathies Products under Development by Companies151
Familial Amyloid Neuropathies Products under Investigation by Universities/Institutes161
Familial Amyloid Neuropathies Companies Involved in Therapeutics Development175
  Alnylam Pharmaceuticals, Inc.171
  Bsim2181
  GlaxoSmithKline Plc191
  Pfizer Inc.201
  SOM Innovation Biotech SL211
Familial Amyloid Neuropathies Therapeutics Assessment229
  Assessment by Monotherapy Products221
  Assessment by Target232
  Assessment by Mechanism of Action252
  Assessment by Route of Administration272
  Assessment by Molecule Type292
Drug Profiles3116
  CLR-01 - Drug Profile311
    Product Description311
    Mechanism of Action311
    R&D Progress312
  doxycycline hyclate - Drug Profile331
    Product Description331
    Mechanism of Action331
    R&D Progress331
  inotersen sodium - Drug Profile341
    Product Description341
    Mechanism of Action341
    R&D Progress342
  Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile361
    Product Description361
    Mechanism of Action361
    R&D Progress361
  patisiran - Drug Profile371
    Product Description371
    Mechanism of Action371
    R&D Progress371
  revusiran - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress383
  Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile411
    Product Description411
    Mechanism of Action411
    R&D Progress411
  Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  tafamidis meglumine - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress432
  tolcapone - Drug Profile451
    Product Description451
    Mechanism of Action451
    R&D Progress452
Familial Amyloid Neuropathies Recent Pipeline Updates4715
Familial Amyloid Neuropathies - Dormant Projects621
Familial Amyloid Neuropathies Product Development Milestones6312
  Featured News &Press Releases631
    May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program631
    Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)632
    Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)651
    Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis661
    Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting671
    Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)682
    Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis701
    Oct 27, 2015: Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update711
    Sep 28, 2015: Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin Monomers and Oligomers in TTR-Mediated Amyloidosis Patients with Familial Amyloidotic Polyneuropathy712
    Jul 20, 2015: Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis732
Appendix752
  Methodology751
  Coverage751
  Secondary Research751
  Primary Research751
  Expert Panel Validation751
  Contact Us751
  Disclaimer761

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Familial Amyloid Neuropathies - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Familial-Amyloid-Neuropathies-Pipeline-Review-H1-2016-2088-15926>
  
APA:
Global Markets Direct - Market Research. (2016). Familial Amyloid Neuropathies - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Familial-Amyloid-Neuropathies-Pipeline-Review-H1-2016-2088-15926>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.